234 related articles for article (PubMed ID: 21712425)
1. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
[TBL] [Abstract][Full Text] [Related]
3. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Cao X; Mitra AK; Pounds S; Crews KR; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
Pharmacogenomics; 2013 Sep; 14(12):1449-66. PubMed ID: 24024897
[TBL] [Abstract][Full Text] [Related]
4. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
5. Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.
Galmarini CM; Graham K; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Mackey JR; Dumontet C
Blood; 2001 Sep; 98(6):1922-6. PubMed ID: 11535530
[TBL] [Abstract][Full Text] [Related]
6. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
7. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
[TBL] [Abstract][Full Text] [Related]
8. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.
Hartford CM; Duan S; Delaney SM; Mi S; Kistner EO; Lamba JK; Huang RS; Dolan ME
Blood; 2009 Mar; 113(10):2145-53. PubMed ID: 19109566
[TBL] [Abstract][Full Text] [Related]
9. Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
Aksoy P; Zhu MJ; Kalari KR; Moon I; Pelleymounter LL; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2009 Aug; 19(8):567-76. PubMed ID: 19623099
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
11. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
Jordheim LP; Nguyen-Dumont T; Thomas X; Dumontet C; Tavtigian SV
Drug Metab Dispos; 2008 Dec; 36(12):2419-23. PubMed ID: 18775979
[TBL] [Abstract][Full Text] [Related]
12. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
Cheong HS; Koh Y; Ahn KS; Lee C; Shin HD; Yoon SS
Pharmacogenet Genomics; 2014 Sep; 24(9):436-41. PubMed ID: 25000516
[TBL] [Abstract][Full Text] [Related]
13. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
14. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
[TBL] [Abstract][Full Text] [Related]
15. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.
Yin B; Kogan SC; Dickins RA; Lowe SW; Largaespada DA
Exp Hematol; 2006 May; 34(5):631-41. PubMed ID: 16647569
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.
Galmarini CM; Cros E; Thomas X; Jordheim L; Dumontet C
Haematologica; 2005 Dec; 90(12):1699-701. PubMed ID: 16330448
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
Suzuki K; Sugawara T; Oyake T; Uchiyama T; Aoki Y; Tsukushi Y; Onodera S; Ito S; Murai K; Ishida Y
Leuk Res; 2007 Oct; 31(10):1343-9. PubMed ID: 17350683
[TBL] [Abstract][Full Text] [Related]
18. Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia.
Jiang C; Yang W; Moriyama T; Liu C; Smith C; Yang W; Qian M; Li Z; Tulstrup M; Schmiegelow K; Crews KR; Zhang H; Pui CH; Evans W; Relling M; Bhatia S; Yang JJ
Clin Pharmacol Ther; 2021 Jun; 109(6):1538-1545. PubMed ID: 33124053
[TBL] [Abstract][Full Text] [Related]
19. 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J; Rodríguez-Romanos R; Coll R; Osca G; Pratcorona M; González-Bártulos M; Garrido A; Angona A; Talarn C; Tormo M; Arnan M; Vives S; Salamero O; Tuset E; Lloveras N; Díez I; Zamora L; Bargay J; Sampol A; Cruz D; Vila J; Sitges M; Garcia A; Vall-Llovera F; Esteve J; Sierra J; Gallardo D;
Eur J Haematol; 2022 Dec; 109(6):755-764. PubMed ID: 36063368
[TBL] [Abstract][Full Text] [Related]
20. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
